897 related articles for article (PubMed ID: 24953157)
1. Bordetella pertussis and pertactin-deficient clinical isolates: lessons for pertussis vaccines.
Hegerle N; Guiso N
Expert Rev Vaccines; 2014 Sep; 13(9):1135-46. PubMed ID: 24953157
[TBL] [Abstract][Full Text] [Related]
2. Pertactin-Negative and Filamentous Hemagglutinin-Negative Bordetella pertussis, Australia, 2013-2017.
Xu Z; Octavia S; Luu LDW; Payne M; Timms V; Tay CY; Keil AD; Sintchenko V; Guiso N; Lan R
Emerg Infect Dis; 2019 Jun; 25(6):1196-1199. PubMed ID: 31107218
[TBL] [Abstract][Full Text] [Related]
3. Pertactin deficient Bordetella pertussis present a better fitness in mice immunized with an acellular pertussis vaccine.
Hegerle N; Dore G; Guiso N
Vaccine; 2014 Nov; 32(49):6597-600. PubMed ID: 25312274
[TBL] [Abstract][Full Text] [Related]
4. Rare Detection of Bordetella pertussis Pertactin-Deficient Strains in Argentina.
Carriquiriborde F; Regidor V; Aispuro PM; Magali G; Bartel E; Bottero D; Hozbor D
Emerg Infect Dis; 2019 Nov; 25(11):2048-2054. PubMed ID: 31625838
[TBL] [Abstract][Full Text] [Related]
5. Rapid increase in pertactin-deficient Bordetella pertussis isolates, Australia.
Lam C; Octavia S; Ricafort L; Sintchenko V; Gilbert GL; Wood N; McIntyre P; Marshall H; Guiso N; Keil AD; Lawrence A; Robson J; Hogg G; Lan R
Emerg Infect Dis; 2014 Apr; 20(4):626-33. PubMed ID: 24655754
[TBL] [Abstract][Full Text] [Related]
6. Pertactin-negative Bordetella pertussis strains: evidence for a possible selective advantage.
Martin SW; Pawloski L; Williams M; Weening K; DeBolt C; Qin X; Reynolds L; Kenyon C; Giambrone G; Kudish K; Miller L; Selvage D; Lee A; Skoff TH; Kamiya H; Cassiday PK; Tondella ML; Clark TA
Clin Infect Dis; 2015 Jan; 60(2):223-7. PubMed ID: 25301209
[TBL] [Abstract][Full Text] [Related]
7. Evolution of French Bordetella pertussis and Bordetella parapertussis isolates: increase of Bordetellae not expressing pertactin.
Hegerle N; Paris AS; Brun D; Dore G; Njamkepo E; Guillot S; Guiso N
Clin Microbiol Infect; 2012 Sep; 18(9):E340-6. PubMed ID: 22717007
[TBL] [Abstract][Full Text] [Related]
8. Pertactin negative Bordetella pertussis demonstrates higher fitness under vaccine selection pressure in a mixed infection model.
Safarchi A; Octavia S; Luu LD; Tay CY; Sintchenko V; Wood N; Marshall H; McIntyre P; Lan R
Vaccine; 2015 Nov; 33(46):6277-81. PubMed ID: 26432908
[TBL] [Abstract][Full Text] [Related]
9. Bordetella pertussis Strain Lacking Pertactin and Pertussis Toxin.
Williams MM; Sen K; Weigand MR; Skoff TH; Cunningham VA; Halse TA; Tondella ML;
Emerg Infect Dis; 2016 Feb; 22(2):319-322. PubMed ID: 26812174
[TBL] [Abstract][Full Text] [Related]
10. Pertactin-deficient Bordetella pertussis isolates in Poland-a country with whole-cell pertussis primary vaccination.
Polak M; Zasada AA; Mosiej E; Krysztopa-Grzybowska K; Witkowski L; Rzeczkowska M; Piekarska K; Lutyńska A
Microbes Infect; 2019; 21(3-4):170-175. PubMed ID: 30580013
[TBL] [Abstract][Full Text] [Related]
11. Evolution of whooping cough bacterium may reduce vaccine effectiveness.
Riedmann EM
Hum Vaccin Immunother; 2014; 10(6):1430. PubMed ID: 25396233
[No Abstract] [Full Text] [Related]
12. Pertactin-negative variants of Bordetella pertussis in New York State: a retrospective analysis, 2004-2013.
Quinlan T; Musser KA; Currenti SA; Zansky SM; Halse TA
Mol Cell Probes; 2014 Aug; 28(4):138-40. PubMed ID: 24365130
[TBL] [Abstract][Full Text] [Related]
13. Bordetella pertussis pertactin knock-out strains reveal immunomodulatory properties of this virulence factor.
Hovingh ES; Mariman R; Solans L; Hijdra D; Hamstra HJ; Jongerius I; van Gent M; Mooi F; Locht C; Pinelli E
Emerg Microbes Infect; 2018 Mar; 7(1):39. PubMed ID: 29559630
[TBL] [Abstract][Full Text] [Related]
14. Genetic and antigenic analysis of Bordetella pertussis isolates recovered from clinical cases in Ontario, Canada, before and after the introduction of the acellular pertussis vaccine.
Tsang RS; Sill ML; Martin IE; Jamieson F
Can J Microbiol; 2005 Oct; 51(10):887-92. PubMed ID: 16333349
[TBL] [Abstract][Full Text] [Related]
15. Genome characteristics of
Ben Fraj I; Bouchez V; Smaoui H; Kechrid A; Brisse S
J Med Microbiol; 2019 Sep; 68(9):1320-1323. PubMed ID: 31329091
[TBL] [Abstract][Full Text] [Related]
16. [Modern strains of Bordetella pertussis: immunobiological properties and vaccine improvement].
Shinkarev AS; Mertsalova NU; Mazurova IK; Borisova OIu; Zakharova NS; Ozeretskovskaia MN; Zaĭtsev EM; Poddubikov AV; Britsina MV; Bazhanova IG
Zh Mikrobiol Epidemiol Immunobiol; 2007; (4):20-5. PubMed ID: 17886371
[TBL] [Abstract][Full Text] [Related]
17. Shifts of Bordetella pertussis variants in Sweden from 1970 to 2003, during three periods marked by different vaccination programs.
Hallander HO; Advani A; Donnelly D; Gustafsson L; Carlsson RM
J Clin Microbiol; 2005 Jun; 43(6):2856-65. PubMed ID: 15956409
[TBL] [Abstract][Full Text] [Related]
18. Pertactin-deficient
Barkoff AM; Mertsola J; Pierard D; Dalby T; Hoegh SV; Guillot S; Stefanelli P; van Gent M; Berbers G; Vestrheim D; Greve-Isdahl M; Wehlin L; Ljungman M; Fry NK; Markey K; He Q
Euro Surveill; 2019 Feb; 24(7):. PubMed ID: 30782265
[TBL] [Abstract][Full Text] [Related]
19. [Evaluation of whole-cell and acellular pertussis vaccines effectiveness in clearance of experimental B. pertussis infection in mice].
Gzyl A; Augustynowicz E; Zawadka M; Rabczenko D; Slusarczyk J
Med Dosw Mikrobiol; 2007; 59(2):123-35. PubMed ID: 17929410
[TBL] [Abstract][Full Text] [Related]
20. Clinical Manifestations and Molecular Characterization of Pertactin-Deficient and Pertactin-Producing Bordetella pertussis in Children, Philadelphia 2007-2014.
Vodzak J; Queenan AM; Souder E; Evangelista AT; Long SS
Clin Infect Dis; 2017 Jan; 64(1):60-66. PubMed ID: 27624959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
